drugset / Trial / NCT00257920

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

NCT00257920

Phase 4 Completed 41 enrolled Abbott
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of Zemplar® Injection and Hectorol® Injection on intestinal calcium absorption in Chronic Kidney Disease Stage 5 subjects on hemodialysis.

Timeline

Start
2006-06
Primary completion
2008-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Doxercalciferol Small molecule 3.6 ug
Comparator Paricalcitol Other / unclassified 6 ug